Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cobimetinib in Refractory Histiocytic Disorders
NCT04079179Phase 2Recruiting
- Start
- Apr 2021
- Primary completion
- Jan 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cobimetinib in Langerhans cell histiocytosis (LCH), juvenile xanthogranuloma (JXG), Erdheim-Chester disease (ECD), Rosai-Dorfman disease (RDD), histiocytic sarcoma (HS). Started Apr 2021; status: recruiting.
02
Drugs
cobimetinib
03
Conditions
Langerhans cell histiocytosis (LCH)juvenile xanthogranuloma (JXG)Erdheim-Chester disease (ECD)Rosai-Dorfman disease (RDD)histiocytic sarcoma (HS)
Beyond the preview
Go deeper on NCT04079179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04079179.